INS and myeloid sarcoma: In patients with NAFLD or MS, insulin does not suppress either the production of triglyceride-rich VLDL particles from the liver or lipolysis [41], which is the main mechanism that contributes to the increase in serum triglycerides in both patients with MS and NAFLD [40].